Health Economics›Acute myeloid leukemia›Relapsed or refractory subsequent lines of therapy

Relapsed or refractory subsequent lines of therapy

Acute myeloid leukemia · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine, Vorinostat, Gemtuzumab ozogamicin Variant #01 Partial	—	R 115 290	28d	—	—	~6	~R 691 738 indirect	—
Cladribine monotherapy Variant #03	—	R 34 921	35d	—	—	~1	~R 34 921 indirect	—
Decitabine monotherapy Variant #01	—	R 32 080	42d	—	~6.7 mo	~2	~R 64 160 PFS proxy · indirect	3
Azacitidine monotherapy Variant #01	—	R 29 332	28d	—	~8.7 mo	~6	~R 175 992 PFS proxy · indirect	11
Ruxolitinib monotherapy Variant #06	—	R 24 260	—	—	—	~2	~R 48 520 PFS proxy · indirect	2
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01	—	R 1 560	28d	—	7.6 mo	6	R 9 359 PFS proxy	1
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 1 249	28d	—	4.7 mo	6	R 7 491 PFS proxy	1
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	~12	—	1

8 of 8 regimens shown